PRODUCT PIPELINE
Blue Earth Diagnostics’ commitment is to develop and commercialise innovative radiopharmaceutical agents that have the potential to inform management decisions or treat patients with serious disease, such as cancer. These agents are designed to have a positive impact on patient care, with a focus on areas of significant unmet medical need. Here you can explore details of our research pipeline, arranged by product.
|
Product/Candidate
|
DISEASE/THERAPEUTIC AREA
|
Application
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
|
fluciclovine(18F) |
Brain metastases |
PET imaging |
|
|
|
|
|
rhPSMA-7.3(18F) |
Prostate cancer |
PET imaging |
|
|
|
|
|
FAP-targeted technology |
Multiple solid tumours |
PET imaging
|
|
Abbreviations:
PET = Positron Emission Tomography
rhPSMA = radiohybrid Prostate-Specific Membrane Antigen
FAP = Fibroblast Activation Protein
Our sister company, Blue Earth Therapeutics, continues to investigate the use of rhPSMA-10.1 as a therapeutic agent. For more information see
https://www.blueearththerapeutics.com/pipeline
PP-UK-0565 / November 2022
